Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Prothena Community
NasdaqGS:PRTA Community
1
Narratives
written by author
0
Comments
on narratives written by author
7
Fair Values set
on narratives written by author
Community Investing Ideas
Prothena
Popular
Undervalued
Overvalued
Prothena
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities
Key Takeaways Successful clinical trials for Birtamimab and Alzheimer's treatments could significantly boost Prothena's revenue through large market opportunities. Strategic partnerships and a strong financial position support pipeline advancement and potential long-term earnings growth.
View narrative
US$24.29
FV
66.0% undervalued
intrinsic discount
14.82%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
25 days ago
author updated this narrative
Your Valuation for
PRTA
PRTA
Prothena
Your Fair Value
US$
Current Price
US$8.25
20.3% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-433m
217m
2015
2018
2021
2024
2025
2027
2030
Revenue US$87.9m
Earnings US$18.4m
Advanced
Set Fair Value